Literature DB >> 6407878

Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins.

R V Haning, C W Austin, I H Carlson, D L Kuzma, S S Shapiro, W J Zweibel.   

Abstract

In order to compare the effectiveness of 8:00 A.M. plasma 17 beta-estradiol (E2), 24-hour urinary estriol glucuronide (E3G), and ultrasound as predictors of ovarian hyperstimulation, 70 cycles of induction of ovulation with 5:00 P.M. to 8:00 P.M. injection of menotropins from 28 subjects were evaluated. Hyperstimulation was four times more frequent in pregnancy than in nonpregnancy cycles (P less than 0.005). The hyperstimulation score (range, 0 to 6) was correlated with plasma E2 (0.63, P less than 0.01), the number of follicles (0.31, P less than 0.05), the duration of treatment (0.31, P less than 0.05), and urinary E3G (0.25, P less than 0.05). Plasma E2 was the best predictor of the hyperstimulation score, and plasma E2 was far superior to both urinary E3G and the number of follicles. Management with ultrasound alone is insufficient to prevent severe ovarian hyperstimulation. With this protocol, human chorionic gonadotropin may be given as soon as the first follicle reaches 1.4 cm in diameter as long as plasma E2 is less than 4000 pg/ml. The values of plasma E2 are dependent on the interval between blood sampling and injection of menotropins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407878     DOI: 10.1016/s0015-0282(16)47173-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

Review 1.  Ovarian hyperstimulation syndrome: a review of pathophysiology.

Authors:  P A Bergh; D Navot
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

2.  Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.

Authors:  Jhansi Reddy; Volkan Turan; Giuliano Bedoschi; Fred Moy; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2014-05-23       Impact factor: 3.412

Review 3.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

4.  OVARIAN HYPERSTIMULATION SYNDROME DURING INDUCTION OF OVULATION FOR INTRA UTERINE INSEMINATION.

Authors:  S K Rath; R K Sharma; P Tarneja; A B Chattopadhyay; R D Wadhwa
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Ovarian hyperstimulation syndrome complicated by uterine prolapse.

Authors:  A B Copperman; T Mukherjee; L Grunfeld; B Sandler; M Bustillo
Journal:  J Assist Reprod Genet       Date:  1995-05       Impact factor: 3.412

6.  The clinical ramifications of polycystic ovarian morphology in oocyte donors.

Authors:  M Cho; G Ambartsumyan; H Danzer; K Brennan; M Surrey
Journal:  J Assist Reprod Genet       Date:  2013-01-05       Impact factor: 3.412

Review 7.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

8.  Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome.

Authors:  M A Aboulghar; R T Mansour; G I Serour; I Elattar; Y Amin
Journal:  J Assist Reprod Genet       Date:  1992-06       Impact factor: 3.412

9.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

10.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.

Authors:  E R Levin; G F Rosen; D L Cassidenti; B Yee; D Meldrum; A Wisot; A Pedram
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.